Posted on March 8th, 2009 by
Results from a recent study indicate that the addition of the drug cisplatin (Platinol®) did not improve response rates, survival rates, or progression-free survival for patients with gatric cancer. These findings were published in The Annals of Oncology.
Gastric cancer forms in the tissues and lining of the stomach as the result of causes not fully understood. It is estimated that approximately 21,500 new cases will occur in 2008 in the United States and that gastric cancer will be responsible for 10,800 deaths. Current treatment options include surgery, chemotherapy, and radiation. Research is ongoing to determine which therapy or combination of therapies produces the best outcome while still being tolerable for the patient.
In the current trial, researchers from Korea randomly assigned untreated patients diagnosed with gastric cancer to receive chemotherapy with either the drugs Camptosar® (irinotecan), leucovorin, and 5-Fu (ILF regimen) or irinotecan, leucovorin, 5-Fu, and cisplatin (PILF regimen). Treatment was repeated every two weeks and included 45 patients treated with ILF and 45 patients treated with PILF.
Researchers concluded that although both treatment regimens were effective in the initial treatment of gastric cancer, the addition of cisplatin provided no clear advantage in overall survival, response rates, or progression-free survival.
Reference: Park, S., Nam, E., Park, J. et al. Randomized Phase II study of irinotecan, leucovorin, and 5-flourouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of Oncology. 2008; 19(4): 729-733.
Related News: Combination Chemotherapy Has Potential as Standard Treatment for Advanced Gastric Cancer (3/3/2008)
Copyright © 2010 CancerConsultants. All Rights Reserved.
Tags: UNM CC Features
You must be logged-in to the site to post a comment.